Literature DB >> 16093201

Three generations of cyclosporine a formulations: an in vitro comparison.

Katrin Thomas1, Christoph Koelwel, Uwe Machei, Lothar Färber, Achim Göpferich.   

Abstract

When the microemulsion formulation of the critical dose drug cyclosporine A (CsA) (Sandimmun Optoral) was introduced in the mid-1990s, it became clear that this new formulation improves the oral bioavailability of CsA and has a positive influence on its pharmacokinetic variability. Previous studies with the original CsA formulation (Sandimmun) showed that the size of the emulsion droplets and concomitant food intake has an effect on the absorption of CsA from the small intestine when orally administered. It was suggested that these effects might have an influence on the drugs' pharmacokinetic parameters. In this study, we focused on the two above-mentioned aspects and compared the first and second generations of CsA products (Sandimmun, Sandimmun Optoral) to generic CsA formulations by analyzing the contents of cyclosporine A gel capsules with respect to their emulsion droplet and micelle sizes using photon correlation spectroscopy (PCS). We tried to discern any differences in droplet size between different generations of CsA formulations, primarily the second and third generation, through simple physical tests. Because a high fat content food may influence the absorption of CsA, we also determined the distribution of CsA between hydrophilic and lipophilic phases using high-performance liquid chromatography analysis. It became clear that when compared under simple physical conditions, established cyclosporine formulations and new generic products show significant differences in droplet size and distribution between an aqueous phase and a high fat content food. Whether these differences are of clinical relevance remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093201     DOI: 10.1081/ddc-54311

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  3 in total

1.  Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe.

Authors:  Atholl Johnston; Roland Asmar; Björn Dahlöf; Kate Hill; David Albert Jones; Jens Jordan; Michael Livingston; Graham Macgregor; Michael Sobanja; Panagiotis Stafylas; Enrico Agabiti Rosei; José Zamorano
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 2.  Nanomedicines in renal transplant rejection--focus on sirolimus.

Authors:  Li-Jiuan Shen; Fe-Lin Lin Wu
Journal:  Int J Nanomedicine       Date:  2007

3.  Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.

Authors:  Anna Elgart; Irina Cherniakov; Yanir Aldouby; Abraham J Domb; Amnon Hoffman
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.